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Abstract
Carbon monoxide (CO) is generated during incomplete combus-
tion of carbon-containing compounds and leads to acute and
chronic toxicity in animals and humans depending on the concen-
tration and exposure time. In addition to exogenous sources, CO is
also produced endogenously by the activity of heme oxygenases
(HOs) and the physiological significance of HO-derived CO has
only recently emerged. CO exerts vasoactive, anti-proliferative, anti-
oxidant, anti-inflammatory and anti-apoptotic effects and contri-
butes substantially to the important role of the inducible isoform
HO-1 as a mediator of tissue protection and host defense. Exoge-
nous application of low doses of gaseous CO might provide a
powerful tool to protect organs and tissues under various stress
conditions. Experimental evidence strongly suggests a beneficial
effect under pathophysiological conditions such as organ trans-
plantation, ischemia/reperfusion, inflammation, sepsis, or shock
states. The cellular and molecular mechanisms mediating CO
effects are only partially characterized. So far, only a few studies in
humans are available, which, however, do not support the
promising results observed in experimental studies. The protective
effects of exogenous CO may strongly depend on the pathological
condition, the mode, time point and duration of application, the
administered concentration, and on the target tissue and cell.
Differences in bioavailability of endogenous CO production and
exogenous CO supplementation might also provide an explanation
for the lack of protective effects observed in some experimental
and clinical studies. Further randomized, controlled clinical studies
are needed to clarify whether exogenous application of CO may
turn into a safe and effective preventive and therapeutic strategy to
treat pathophysiological conditions associated with inflammatory or
oxidative stress.
Carbon monoxide: exogenous sources and
toxic effects
High concentrations of carbon monoxide (CO) are generated
during incomplete combustion of carbon-containing com-
pounds such as wood, coal, gas, oil, or tobacco. CO is a
colorless and odorless gas that causes acute and chronic
toxicity in humans and animals. CO mediates its toxic effects
primarily by strongly binding to hemoglobin and forming
carboxyhemoglobin (COHb), thereby reducing the oxygen-
carrying capacity of the blood. The affinity of hemoglobin for
CO is approximately 210 to 250 times that for oxygen [1].
Both decreased arterial oxygen content (impaired O2 binding
to hemoglobin) and decreased tissue oxygen pressure (PO2;
increased affinity of COHb for O2) lead to tissue hypoxia
[2,3]. There is a linear correlation between the inspired level
of CO and arterial COHb levels [4]. Although the percentage
of COHb in blood represents the best predictive marker for
extrapolating the total amount of CO, COHb levels do not
always correlate with the degree of injury and outcome [5].
COHb levels between 15 and 20% seem to be well tolerated
in humans and are considered the ‘biological threshold’
above which severe CO-mediated injury is likely to occur [6].
In addition to hemoglobin, CO binding to other heme-
containing proteins, such as cytochrome c oxidase (thus
interfering with cellular respiration), catalase, or myoglobin,
may partly contribute to the toxic effects.
The most vulnerable organs to CO-induced hypoxia are the
heart and the brain because of their high metabolic rate [7].
The mild symptoms of acute CO poisoning are often non-
specific and include headache, nausea, vomiting, dizziness,
and fatigue, which may progress to confusion, tachypnea,
tachycardia, impaired vision and hearing, convulsions, loss of
consciousness, finally leading to death when immediate and
adequate treatment is not available. The amount of CO
inhaled and/or the exposure time are the most critical factors
that determine the severity of CO poisoning. In addition,
children and older adults are more susceptible and may have
more severe symptoms [8]. Predisposing conditions for CO
toxicity have been described, such as cardiovascular dis-
orders (for example, coronary heart disease), chronic obstruc-
tive pulmonary disease (COPD), or anemia [9]. Heavy
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smokers may have more severe symptoms since their COHb
levels are already elevated.
Carbon monoxide appears to be the leading cause of injury
and death due to poisoning worldwide [10]. Since tissue
hypoxia is the underlying mechanism of CO-induced injury,
increasing the inspired oxygen concentration represents the
treatment for CO poisoning. In severe poisoning, hyperbaric
oxygen therapy is regarded as the therapy of choice [11].
Both normobaric and hyperbaric oxygen improve oxygen
delivery by increasing the amount of oxygen dissolved in
plasma and by reducing the half-life of COHb. However, the
results from existing randomized, controlled trials of hyper-
baric versus normobaric oxygen in the treatment of acute CO
poisoning provide conflicting results regarding the effective-
ness of hyperbaric oxygen for the prevention of neurological
symptoms [12]. An ongoing phase IV randomized clinical trial
investigates important clinical outcomes (for example, 6-week
cognitive sequelae) of patients with acute CO poisoning
randomized to receive either one or three hyperbaric oxygen
treatments [13]. The estimated study completion date is May
2009. If treatment of CO poisoning is timely, most patients
are able to recover, but even with adequate treatment CO
poisoning may result in permanent memory loss or brain
damage. For the long-term sequelae of acute CO poisoning,
only symptomatic therapy is available. Chronic exposure to
CO may lead to myocardial hypertrophy [14].
Functions of endogenous carbon monoxide
production
Coburn and colleagues [15] demonstrated that CO is
endogenously produced in animals and humans. The vast
majority of endogenous CO is derived from the oxidative
breakdown of heme by microsomal heme oxygenases (HOs).
HO catalyzes the first and rate-limiting step in heme degrada-
tion, yielding equimolar amounts of CO, iron, and biliverdin-
IXα (Figure 1), which is further converted to bilirubin by
biliverdin reductase [16]. Two isoforms of HO have been
described, namely HO-1 [17,18] and HO-2 [19,20]. Further-
more, a third isoform has been found in rats [21], which
represents a processed pseudogene derived from the gene
for HO-2 [22]. HO-2 is constitutively expressed in many
tissues, with high activity in testes, central nervous system,
liver, kidney, and intestine. A basal expression of HO-1 is
found in tissues that degrade senescent red blood cells, pre-
dominantly spleen, reticuloendothelial cells of the liver and
bone marrow [23]. HO-1 is the inducible isoform, and induc-
tion of HO-1 gene expression occurs in response to a wide
variety of endogenous and exogenous stimuli, such as
chemical or physical stimuli, xenobiotics, hyperoxia, hypoxia,
ischemia/reperfusion, inflammation, surgical procedures, or
anesthetics [24-29].
The critical role of HO-1 under physiological conditions was
demonstrated in the first described case of human HO-1
deficiency. The boy in this case presented with severe growth
retardation, persistent hemolytic anemia, and severe,
persistent endothelial damage [30] and died at the age of
6 years [31]. Over the past decade the function of HO-1 has
expanded from a heme-degrading enzyme to a key mediator
of tissue protection and host defense, and its cytoprotective
effects have been described in vivo and  in vitro
[24,25,28,32-42].
The products of the HO pathway - CO, iron, and biliverdin/
bilirubin - have long been regarded solely as waste products.
Recently, the unique biological functions of the products and
their contribution to the protective effects of the HO system
have attracted great interest. Thus, the HO system has
different functions: besides the breakdown of heme, a pro-
oxidant [43], it produces cytoprotective substances, and the
inducibility of HO-1 renders it a powerful endogenous
cytoprotective system.
Bilirubin has been described as a potent endogenous anti-
oxidant [44] with potential clinical implications [45]. Free iron
exhibits oxidizing capacities, although the iron released during
heme degradation stimulates the synthesis of ferritin [46],
which sequesters unbound iron, thereby serving as an
additional anti-oxidant [47]. The observation that CO can
weakly activate soluble guanylate cyclase (sGC), thereby
stimulating the production of cGMP, suggested an important
role of CO as an intracellular messenger molecule, thus
acting in a similar way to nitric oxide [48,49]. The functions of
CO as a neural messenger have since been described [50].
Vasoactive effects of CO have been reported in the
pulmonary vasculature [51] and in the liver [37,52], where
CO acts to maintain portal venous vascular tone in a relaxed
state [37]. In addition to the biological functions of CO under
physiological conditions, the substantial contribution of CO
to the protective effects of induced HO activity has recently
been recognized and includes vasoactive, anti-oxidative, anti-
inflammatory, anti-apoptotic, and anti-proliferative properties.
Thus, CO has advanced from a toxic waste product to a
physiological regulator and the importance of endogenously
derived CO to control homeostasis under both physiological
and pathophysiological conditions is increasingly recognized
in every organ system and cell type.
Although different mechanisms explaining the effects of CO
have been described, the exact underlying signaling mecha-
nisms and precise molecular targets of CO are only partially
elucidated. Effects mediated by CO-induced activation of
sGC/cGMP include inhibition of platelet activation and
aggregation, smooth muscle relaxation, vasoactive effects,
inhibition of cellular proliferation, and effects on neurotrans-
mission [37,49-56]. cGMP-independent mechanisms of
vasoregulation have also been suggested. CO may directly
activate calcium-dependent potassium channels, thus
mediating dilation of blood vessels [57]. Recent evidence
suggests an important role of CO as a signaling molecule in
modulating mitogen-activated protein kinases (MAPKs),especially p38 MAPK in response to oxidative stress and
inflammation (reviewed in [58,59]). CO-mediated activation
of p38 MAPK has been shown to exert anti-inflammatory [60],
anti-apoptotic, and anti-proliferative effects [61,62]. Down-
stream target molecules of CO-dependent p38 MAPK
activation have been identified, namely heat shock protein 70
and caveolin-1 [61,62]. Zhang and colleagues [63] demon-
strated that the anti-apoptotic effects of CO involve both
phosphatidylinositol 3-kinase/Akt and p38 MAPK signaling
pathways in endothelial cells in a model of anoxia-reoxygena-
tion injury. In hepatocytes, CO activated nuclear factor-κB
(NF-κB) through a mechanism that involves reactive oxygen
species-induced Akt phosphorylation and protected against
cell death [64]. Figure 2 provides a simplified overview of the
described CO-mediated signal transduction pathways.
Therapeutic applications of carbon monoxide
The observation that induction of HO-1 gene expression
under pathological conditions plays an important role in organ
preservation strongly suggests that CO might be
substantially involved in mediating these effects. This is
supported by the observation in models of HO-1 deficiency
or after blockade of HO activity that the protective effects of
induction of HO-1 are mimicked by low amounts of
exogenous CO [54,59,65]. However, pre-induction of the
HO-1 system by exogenous stimuli to induce local CO
release or exogenous application of CO to potentiate the
endogenous protective effects may be challenging. To
increase the availability of CO, different approaches have
been developed, including induction of HO-1 gene expres-
sion with pharmacological and genetic strategies, inhalation
of low doses of CO, and application of CO-releasing
molecules. Figure 3 briefly summarizes the protective effects
and the potential therapeutic applications of CO in a variety
of disorders and diseases of different organ systems.
Induction of HO-1 gene expression
Strategies to induce HO-1 as a protective mechanism
against a subsequent stress event include pharmacological
approaches such as volatile anesthetics [40] or heme
derivatives [32,33], and genetic approaches [39] as well as
the use of other inducers as described above. Long-term
overexpression of HO-1 by targeted gene transfer has
become a powerful tool to investigate the specific role of the
HO-1 enzyme [66]. The amount of CO released by the
induced activity of HO-1 is unknown. In addition, induction of
HO-1 increases the concentration of all products of the
pathway, and the contribution of CO to the observed
protective effects is difficult to evaluate.
Exogenous application of carbon monoxide
Inhalation of CO represents a novel therapeutic approach
and exerts both local effects on the lungs and systemic
effects. The challenge remains to reach safe and effective
concentrations in target tissues without producing
deleterious effects caused by CO-mediated tissue hypoxia.
The tolerance to CO exposure has been investigated in
rodents and conflicting results have been obtained: while
continuous application of 500 ppm CO for 2 years had no
deleterious effects [67], 200 ppm for 20 h per day over
14 days induced myocardial hypertrophy [14].
The CO-releasing properties of transition metal carbonyls were
first described by Herrman [68]. Motterlini and his group have
developed CO-releasing molecules (CO-RMs) as a new
strategy to deliver defined amounts of CO for therapeutic
applications [6,69] without significantly affecting COHb levels
[70]. In particular, the synthesis of a water-soluble compound
might be promising. So far, only experimental data are available.
The use of CO-RMs to characterize CO-mediated cytopro-
tection has been reviewed by Foresti and colleagues [6].
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Figure 1
Heme oxygenase pathway. Heme oxygenase catalyzes the rate-limiting step in the degradation of heme leading to the generation of equimolar
amounts of free iron, biliverdin and carbon monoxide.Preclinical experimental studies
In most experimental models, acute rather than chronic
inhalation of CO is applied (10 to 1,000 ppm for 1 to 24 h).
Depending on the concentration, different exposure times are
required to reach COHb equilibrium [71]. CO inhalation has
been shown to be protective in experimental inflammatory
and non-inflammatory disease models (reviewed in [6,25,
72-75]). The majority of studies investigating the effects of
low amounts of inhaled CO concentrate on disease models in
the lungs. In addition to local effects in the lungs, inhaled CO
is also able to affect systemic organ dysfunction.
Lung  The protective effects of inhaled CO have been investi-
gated in models of acute lung injury, acute respiratory
distress syndrome (ARDS), ischemia/reperfusion, asthma,
and remote lung injury. The first in vivo evidence to suggest a
therapeutic potential of low dose gaseous CO was provided
by Otterbein and colleagues [76]. Rats exposed to low
concentrations of CO exhibited a significant attenuation of
hyperoxia-induced lung injury and increased survival. CO
exposure exerted anti-inflammatory and anti-apoptotic effects.
The molecular mechanisms of the observed inhibition of pro-
inflammatory cytokines involve the MKK3/p38 MAPK pathway
[77]. In contrast, low levels of CO were not protective in a
similar rat model of hyperoxic acute lung injury [4]. Inhalation
of CO attenuated the development of hypoxia-induced
pulmonary artery hypertension in rats, presumably through
activation of Ca2+-activated K+ channels [78] and was also
able to reverse established pulmonary hypertension [79].
Inhalation of CO for 6 h after intratracheal injection of acidic
solution in mice reduced early neutrophil recruitment without
affecting chemokine levels in bronchoalveolar fluid [80]. The
pathomechanisms of allergen-induced asthma include inflam-
mation and bronchoconstriction. In ovalbumin-induced asthma,
CO treatment of mice for 2 h before aerosol challenge led to
a specific reduction of the pro-inflammatory cytokine IL-5
while other pro-inflammatory or anti-inflammatory cytokines
were unaffected [81]. In the same model of inflammation,
Ameredes and colleagues [82] showed a CO-induced,
cGMP-dependent reduction of airway hyper-responsiveness.
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Figure 2
Carbon monoxide signal transduction pathways. CO, carbon monoxide; HSF, heat shock factor; HSP, heat shock protein; MAPK, mitogen-
activated protein kinase; NFκB, nuclear factor-κB; NO, nitric oxide; sGC, soluble guanylate cyclase.
Figure 3
Protective effects and potential therapeutic applications of carbon monoxide. ALI, acute lung injury; ARDS, acute respiratory distress syndrome;
CO, carbon monoxide; I/R, ischemia/reperfusion.In experimental models of lung ischemia and reperfusion,
including transplantation, inhaled CO has anti-inflammatory
and anti-apoptotic effects [54,63,83-86]. The p38 MAPK
pathway and downstream target genes, such as that for early
growth response-1 (Egr-1), seem to play important roles in
mediating the CO effects [84].
Mechanical ventilation may cause profound lung injury and
inflammatory responses. Dolinay and colleagues [87] des-
cribed a CO-mediated suppression of tumor necrosis factor
(TNF)-alpha release and neutrophil recruitment and postu-
lated an involvement of the p38 MAPK pathway. A study in
knock-out mice suggests a key role of Egr-1 as a pro-inflam-
matory regulator in ventilator-induced lung injury. Moreover,
peroxysome proliferator-activated receptor-gamma, an anti-
inflammatory nuclear regulator, seems to be involved in the
protective effects of CO [88].
In addition to attenuating local lung injury, CO also protects
against remote lung injury. After ischemia and reperfusion of
the lower extremities, CO significantly reduced ischemia/
reperfusion-induced acute lung injury [89]. Pretreatment with
inhaled CO reduced pulmonary inflammatory response and
provided anti-apoptotic effects in a model of cardiopulmonary
bypass in pigs [90].
Liver Effects of CO on the liver have been investigated in
models of inflammation- and ischemia/reperfusion-induced
hepatocellular injury as well as in burn injury. TNF-alpha-
induced hepatocyte cell death in mice was prevented by CO
inhalation. CO-induced activation of NF-κB and inducible
nitric oxide synthase and nitric oxide-induced HO-1
expression were required for the protective effects [91]. In
addition, CO-stimulated liver ATP generation through the
activation of sGC was a prerequisite for CO to protect
against TNF-alpha-induced apoptosis [92]. In models of liver
ischemia and reperfusion, HO-1 induction plays an important
role in maintaining hepatocellular integrity [38] and induction
of HO-1 before (low flow) ischemia can attenuate the subse-
quent hepatic injury [32,40]. A role for CO in preventing
hypoxia-induced decreases in hepatocyte ATP levels was
postulated in a mouse model of hemorrhagic shock and
resuscitation [93]. In cold ischemia reperfusion associated
with liver transplantation, CO inhalation suppressed the
inflammatory response. Downregulation of MEK/ERK1/2
seems to play a role in mediating the protective effects while
the NF-κB signaling pathway does not seem to be affected
[94]. CO-RM-liberated CO attenuates liver injury in burn mice
by mechanisms involving downregulation of pro-inflammatory
mediators and suppression of the pro-adhesive phenotype of
endothelial cells [95,96].
Intestine  The protective effects of CO in the intestine have
been investigated in a variety of animal models of post-
operative ileus and cold ischemia/reperfusion injury asso-
ciated with transplantation. The development of postoperative
ileus may occur after mild manipulation of the small bowel
during surgery, which initiates an inflammatory response
within the intestinal muscularis [97] that is characterized by
the release of pro-inflammatory mediators, increased expres-
sion of adhesion molecules on the vascular endothelium, and
recruitment of leukocytes from the systemic circulation
[98,99]. Inhalation of CO significantly attenuated the surgi-
cally induced molecular inflammatory response and the asso-
ciated decline in gastrointestinal contractility that is charac-
teristic of postoperative ileus [100,101]. Similar effects could
be observed after intraperitoneal injection of CO-saturated
Ringer`s lactate solution, possibly in a sGC-dependent
manner [102].
Nakao and colleagues [103] provide a large body of evidence
that inhaled CO is also protective by improving post-
transplant motility and attenuating the inflammatory cytokine
response in the syngeneic rat transplant model. In addition,
CO is anti-apoptotic and significantly improves animal survival
[104]. Similar protective results can be achieved after
storage of grafts in University of Wisconsin solution saturated
with CO [105].
Vascular diseases  Short-term administration of CO has been
shown to be protective against vascular injury. CO rescued
the pro-thrombotic phenotype of Hmox1  deficiency during
oxidative stress [106]. Intravenous injection of CO-saturated
saline produced vasodilatation and improved microvascular
hemodynamics in a hamster skinfold window chamber pre-
paration, possibly via increased cardiac output and local
cGMP content [107]. Otterbein and colleagues [55] des-
cribed a beneficial effect of inhaled CO in preventing arterio-
sclerotic lesions that occur following aorta transplantation.
Heart  Experimental models of heart transplantation or cardio-
pulmonary bypass have been used to investigate CO effects
on accompanying organ injury. CO reduced ischemia/
reperfusion injury and cardiac rejection of mouse to rat
cardiac transplants via anti-apoptotic, anti-inflammatory and
vasodilatory mechanisms, and suppression of platelet aggre-
gation and fibrinolysis [65]. Treatment of the donor (CO
inhalation) and graft (CO-saturated storage solution) but not
the recipient protected against ischemia/reperfusion injury via
anti-apoptotic mechanisms [108]. In contrast, low-dose CO
inhalation of the recipient after transplantation effectively
ameliorated heart allograft rejection via downregulation of
pro-inflammatory mediators [109].
In a clinically relevant model of cardiopulmonary bypass
surgery in pigs, treatment with CO improved cardiac ener-
getics, prevented edema formation and apoptosis, and
facilitated recovery [110]. In a rat model of ischemia/
reperfusion injury induced by occlusion of the left anterior
descending coronary artery, pre-exposure to CO significantly
reduced infarct size and migration of macrophages into
infarct areas. In addition, TNF-alpha expression was reduced.
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activation of p38 MAPK, protein kinase B (Akt), endothelial
nitric oxide synthase, and cGMP in the myocardium [111].
Kidney Most of the studies of CO effects in kidneys
concentrate on models of cold ischemia/reperfusion injury in
transplantation. Ischemia/reperfusion injury of kidney grafts is
one of the major deleterious factors affecting successful renal
transplantation. Renal ischemia/reperfusion injury causes
delayed graft function and plays a significant role in the
development of chronic allograft nephropathy [112,113].
Exposure to low concentrations of CO prevented fibroinflam-
matory changes associated with chronic allograft nephro-
pathy and preserved long-term renal allograft function [114].
Storage of kidneys with cold preservation solutions contain-
ing CO-RMs also improved their function upon reperfusion
[115]. Hypoxia-inducible factor-1-mediated upregulation of
vascular endothelial growth factor seems to contribute to the
protective mechanisms [116]. Nakao and colleagues [117]
provide evidence that prevention of cytochrome P450
degradation, maintenance of normal intracellular heme levels
and a reduction of lipid peroxidation participate in the
protective effects of CO-RMs during storage of kidney grafts.
Systemic inflammation As a model of systemic inflammation,
lipopolysaccharide (LPS)-induced inflammatory response and
organ injury has widely been used to study protective CO-
mediated effects. In rodents and pigs injected with LPS,
inhalation of CO leading to 14.08 ± 1.34% COHb signifi-
cantly reduced LPS-induced cytokine response [118,119]
and improved long-term survival [120]. Further mechanisms
of CO-mediated protection against LPS-induced multiple
injury in rats have been described and include anti-oxidative,
anti-inflammatory and anti-apoptotic effects, and up-regu-
lation of HO-1 expression [121]. In contrast, in a randomized,
controlled study in pigs, CO exposure did not alter LPS-
induced levels of pro- and anti-inflammatory cytokines [122].
The lack of protective effects observed in this study might
possibly be explained by the low level of COHb measured
(5% compared to 14%) [118].
Clinical studies
While a large body of experimental evidence suggests the
potential of low amounts of inhaled CO to protect the lungs
and systemic organs and tissues against oxidative and inflam-
matory insults, only a few studies on therapeutic applications
of CO inhalation in humans have been published.
In a randomized, double-blinded, placebo-controlled, two-way
cross-over trial experimental endotoxemia was induced in
healthy volunteers by injection of 2 ng/kg LPS. The potential
anti-inflammatory effects of CO inhalation were investigated
by inhalation of 500 ppm CO (leading to an increase in
COHb from 1.2% to 7%) versus synthetic air as a placebo
for 1 h. CO inhalation had no effect on the inflammatory
response as measured by systemic cytokine production
(TNF-alpha, IL-6, IL-8, IL-1α and IL-1β) [123]. In this study, no
adverse side effects of CO inhalation were observed.
This study is in contrast to the above described results
obtained in most experimental models of endotoxemia.
Possible explanations for this discrepancy could be that
blood from different species has different affinities for CO,
different COHb half-lives, different hemoglobin CO saturation
points (different COHb levels at the same CO concentration),
or different basic physiologies, such as heart rate.
COPD is characterized by an inflammatory and oxidative
stress response. Furthermore, COPD is accompanied by
increased COHb levels that correlate with exhaled CO [124].
However, the endogenous CO release might not be sufficient
to protect against the development and progression of
COPD. In a randomized, placebo-controlled, cross-over study
20 ex-smoking patients with stable COPD were examined to
assess safety, feasibility, and potential anti-inflammatory
effects of CO inhalation. Inhalation of 100 to 125 ppm CO
for 2 h per day on 4 consecutive days led to a maximal
individual COHb level of 4.5%. In two patients, exacerbations
of COPD occurred during or after the CO inhalation period;
otherwise the treatment was well tolerated. The primary study
endpoint was sputum neutrophil counts. Although there was
a trend towards reduction in sputum eosinophils and
improvement of bronchial responsiveness, no significant
therapeutic effects were observed [125]. The results of this
pilot study are interesting, since they provide some evidence
for a potential therapeutic use of inhaled CO. However,
whether CO inhalation increases the risk of COPD
exacerbations needs to be determined.
One clinical study investigating the effects of low amounts of
inhaled CO is currently in progress [126]. A single blinded,
randomized, placebo controlled phase I study in healthy
subjects investigates the potential of inhaled carbon
monoxide in preventing lung inflammatory responses
following local endotoxin instillation. The study is ongoing, but
currently not recruiting participants.
Conclusion
CO has long been regarded solely as a toxic environmental or
endogenous waste product. In addition to cytoprotective
properties of endogenous CO, recent evidence strongly
suggests protective effects of low concentrations of exoge-
nous CO under pathophysiological conditions such as organ
transplantation, ischemia/reperfusion, inflammation, sepsis, or
shock states. Studies in humans are scarce and so far do not
support the promising results observed in pre-clinical experi-
mental studies. A potential beneficial effect of exogenous CO
may highly depend on the pathological condition, the mode,
time point and duration of application, the administered
concentration, and on the target tissue. Further randomized,
controlled clinical trials are needed to clarify whether exoge-
nous application of CO, either by inhalation or intravenous
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preventive and therapeutic tool to treat pathophysiological
conditions associated with inflammatory or oxidative stress.
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